Earlier this month Danish drugmaker Novo Nordisk launched its oral Wegovy weight-loss pill in the US, for "needle-averse patients". The starting dose is priced at $149 a month for patients paying in ...

Several Indian companies are preparing to launch generic versions of GLP-1 category drug Semaglutide in India ...

Novo Nordisk has had a difficult year as investors questioned the company's ability to translate its strides in pioneering GLP-1 drugs to financial gains. Scientists, however, say that Novo's medicine ...

Billboard has announced an upcoming shift in its chart tabulation that will give more weight to music streaming against album sales. Starting in January, the magazine and authoritative record of music ...

The change is being implemented to reflect an increase in streaming revenue, along with changing music consumption behaviors. By Billboard Staff Starting in January, the Billboard charts will add more ...

ATLANTA -- An investigational quadruple receptor agonist led to a substantial reduction in total body weight with minimal gastrointestinal adverse effects and no observed muscle loss, according to a ...

Sales of Eli Lilly’s blockbuster weight-loss drug Mounjaro have soared in India, making it the top-selling brand in October, just six months after its launch in the world's most populous nation.

Follow along as we build a weight loss tracker in Google Sheets from scratch. You’ll learn how to enter goals, log progress, adjust charts, and print your tracker for an easy way to stay on top of ...

LONDON/COPENHAGEN (Reuters) -Danish drugmaker Novo Nordisk (NYSE: NVO) is facing a major challenge to its blockbuster weight-loss drug Wegovy. Booming sales of Wegovy powered the company to become ...

Michael Ingram is a Senior Contributor from the United States of America. Michael has been writing for GameRant since 2021, writing both analytically and fiction for years beforehand. Michael is a ...

HC Wainwright initiated coverage on Aardvark Therapeutics, Inc. (NASDAQ:AARD) on Monday with a Buy rating and a price forecast of $40. In February, Aardvark Therapeutics, Inc. (NASDAQ:AARD) priced an ...